[
  {
    "ts": null,
    "headline": "Dow Jones Futures: Tech Stocks Eye Key Level; Oracle, Nike, FedEx In Focus",
    "summary": "Futures signal the stock market may test key resistance again after Thursday's Micron-inflation gains. Oracle, FedEx, Nike are early movers.",
    "url": "https://finnhub.io/api/news?id=8030bb19c2481c0f1a00ae5798f3e5221e35d49c6bf053b8b9abf80a95c2163b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1766149757,
      "headline": "Dow Jones Futures: Tech Stocks Eye Key Level; Oracle, Nike, FedEx In Focus",
      "id": 137831370,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Futures signal the stock market may test key resistance again after Thursday's Micron-inflation gains. Oracle, FedEx, Nike are early movers.",
      "url": "https://finnhub.io/api/news?id=8030bb19c2481c0f1a00ae5798f3e5221e35d49c6bf053b8b9abf80a95c2163b"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly’s oral GLP-1RA maintains weight loss from injectable drugs",
    "summary": "Lilly has now submitted a new drug application (NDA) for orforglipron to the FDA for use in adults with obesity.",
    "url": "https://finnhub.io/api/news?id=b86eca1f11891ee028a85b3faaaa3b3f7d42133bf45b2538658bc72b6183679c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1766144440,
      "headline": "Eli Lilly’s oral GLP-1RA maintains weight loss from injectable drugs",
      "id": 137831371,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Lilly has now submitted a new drug application (NDA) for orforglipron to the FDA for use in adults with obesity.",
      "url": "https://finnhub.io/api/news?id=b86eca1f11891ee028a85b3faaaa3b3f7d42133bf45b2538658bc72b6183679c"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk: Oral Wegovy, Supply Chain, And Restructuring = Big Upside Ahead",
    "summary": "Novo Nordisk trades 32% below fair value with a 3.6% yield, semaglutide at 74% of sales, EPS rebound post '26, and pipeline growth. Read why NVO stock is a buy.",
    "url": "https://finnhub.io/api/news?id=b3730fd0dad3c4094fe34c70224541f55e11649c6b036aed36d62f04349144ed",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1766131200,
      "headline": "Novo Nordisk: Oral Wegovy, Supply Chain, And Restructuring = Big Upside Ahead",
      "id": 137830559,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1448618549/image_1448618549.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Novo Nordisk trades 32% below fair value with a 3.6% yield, semaglutide at 74% of sales, EPS rebound post '26, and pipeline growth. Read why NVO stock is a buy.",
      "url": "https://finnhub.io/api/news?id=b3730fd0dad3c4094fe34c70224541f55e11649c6b036aed36d62f04349144ed"
    }
  },
  {
    "ts": null,
    "headline": "Elanco CEO Bites Off More Shares of Fast-Rising Stock",
    "summary": "Elanco Animal Health  stock is having a great year—and Chief Executive Jeffrey Simmons is champing at the bit.  Simmons spent $478,500 to buy 22,000 shares of the stock on Dec. 11 for an average price of $21.75, according to a Form 4 filed with the Securities and Exchange Commission.  The purchase was made by a revocable trust and brings his total indirect ownership to 167,000 shares.",
    "url": "https://finnhub.io/api/news?id=f1a7066ffd0d0f13ddcd114e106d27322a5af1a4be8b7c5e9b5262dbada477d7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1766125800,
      "headline": "Elanco CEO Bites Off More Shares of Fast-Rising Stock",
      "id": 137831372,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Elanco Animal Health  stock is having a great year—and Chief Executive Jeffrey Simmons is champing at the bit.  Simmons spent $478,500 to buy 22,000 shares of the stock on Dec. 11 for an average price of $21.75, according to a Form 4 filed with the Securities and Exchange Commission.  The purchase was made by a revocable trust and brings his total indirect ownership to 167,000 shares.",
      "url": "https://finnhub.io/api/news?id=f1a7066ffd0d0f13ddcd114e106d27322a5af1a4be8b7c5e9b5262dbada477d7"
    }
  },
  {
    "ts": null,
    "headline": "AstraZeneca: Mispriced Growth Following The Oncology Segment Success",
    "summary": "AstraZeneca aims for $80bn revenue by 2030, highlighting oncology advances and growth potential. See AZN stock's valuation insights and GARP investment case.",
    "url": "https://finnhub.io/api/news?id=d922078a6d39841502ab0a542f64330bcda597a46b2e95905ae31285a31da98e",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1766111433,
      "headline": "AstraZeneca: Mispriced Growth Following The Oncology Segment Success",
      "id": 137828830,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2160089493/image_2160089493.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "AstraZeneca aims for $80bn revenue by 2030, highlighting oncology advances and growth potential. See AZN stock's valuation insights and GARP investment case.",
      "url": "https://finnhub.io/api/news?id=d922078a6d39841502ab0a542f64330bcda597a46b2e95905ae31285a31da98e"
    }
  }
]